SciFi Futures
← Concepts
Biotech & Medicine

Engineered organ-donor animals

Transgenic animals bred as living organ farms, carrying human-compatible tissue that can be harvested repeatedly for transplant.

In shortEngineered organ-donor animals, from Oryx and Crake (Margaret Atwood, 2003), is at technology readiness level 5 of 9 (validated in relevant environment) at its weakest link. Held back by Somatic cell nuclear transfer cloning and Durable transplant immune tolerance. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $6.2B–21B.

Pigoons are pigs engineered with multiple human-tissue organ foldouts so that several transplantable organs grow in each animal, bred at OrganInc Farms and eventually feral and dangerous.
Oryx and Crake by Margaret Atwood, 2003

Closest todayGene-edited pig kidneys entered formal clinical trials in late 2025 (10-edit UKidney at NYU Langone, 69-edit EGEN-2784 cleared by FDA); the longest functioning pig kidney in a human lasted 271 days.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • Grafts currently fail to chronic rejection within months despite heavy immunosuppression
    • Chronic antibody-mediated rejection proceeds even under current immunosuppression
    • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
    • No assay predicts which recipients can be safely weaned off drugs
    TRL 5
  • The donor herd itself - edited, cloned, pathogen-free and transplant-qualified - is the technology
    ✕4 blockers›
    • Graft survival measured in months, not years - chronic rejection and thrombotic microangiopathy persist
    • Porcine endogenous retrovirus and novel-zoonosis risk requires lifelong recipient surveillance
    • Organ growth mismatch and porcine protein incompatibilities (complement, coagulation) are only partly corrected by current edit sets
    • Designated-pathogen-free breeding and organ-recovery facilities do not exist at transplant-program scale
    TRL 6
    • Edited cell lines are turned into animals by cloning
      • Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
      • Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
      • Donor egg supply is the limiting input for any primate-scale program
      TRL 5
    • Even heavily edited organs are rejected without durable tolerance
      TRL 5
    • Donor lines need tens of simultaneous edits across rejection, coagulation and retroviral loci
      ✕3 blockers›
      • Structural variants and large deletions accumulate with edit count and are missed by short-read screening
      • Edited cell lines lose clonogenic and developmental potency after many rounds of editing
      • No method reaches the thousands of edits implied by whole-genome rewriting
      TRL 6
      • Higher-fidelity, smaller editor and recombinase proteins are the route to many simultaneous edits
        ✕1 blocker›
        • Designing catalysis and conformational dynamics
        TRL 6
  • Edited founder lines are propagated as cloned animals
    TRL 5
  • Dozens of edits are needed across antigen, complement, coagulation and retroviral loci
    TRL 6
  • Growing extra human-tissue organs inside a host animal is tissue engineering with the animal as the bioreactor
    ✕4 blockers›
    • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
    • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
    • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
    • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
    TRL 4
    • Without a capillary network, tissue thicker than a few hundred microns dies
      ✕3 blockers›
      • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
      • Engineered endothelium is thrombogenic, so perfused constructs clot
      • No method guides anastomosis of a construct's vasculature to host vessels at scale
      TRL 3
    • Banked-cell organs are not patient-matched, so acceptance must be engineered
      TRL 5
    • One organ needs 10^10-10^11 clinical-grade cells of several types
      ✕3 blockers›
      • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
      • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
      • Cost per cell at current media and reagent prices makes a printed organ unaffordable
      TRL 6

Who could unlock it

  • Across several requirements:
  • Colossal Biosciences 2
  • Tatsuo Kawai 2
  • eGenesis 2
Somatic cell nuclear transfer cloningTRL 5bottleneck
  • Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of Sciences
    Cloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
  • Institute of Neuroscience, Chinese Academy of SciencesGovernment lab
    The only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
  • ViaGen Pets and EquineCompany
    The commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
  • Colossal BiosciencesStartup
    Uses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house
Durable transplant immune toleranceTRL 5bottleneck
  • Medeor TherapeuticsStartup
    Its Phase 3 MDR-101 trial left 15 of 20 HLA-matched living-donor kidney recipients functionally tolerant and off all immunosuppression two years after withdrawal, with no graft loss or GVHD (Am J Transplant, 2025)
  • Dixon KaufmanResearcher, University of Wisconsin-Madison
    First author of the MDR-101 Phase 3 report (2025), the first randomised controlled demonstration of durable drug-free tolerance in kidney transplantation
  • Megan SykesResearcher, Columbia Center for Translational Immunology
    Pioneered minimal-conditioning mixed chimerism and xenogeneic thymic transplantation for tolerance; awarded the 2025 Starzl Prize for the path to xenograft tolerance
  • Tatsuo KawaiResearcher, Legorreta Center for Clinical Transplant Tolerance, Massachusetts General Hospital
    Runs the combined kidney and bone-marrow tolerance protocols across HLA barriers and operated on the 2025 engineered-porcine-kidney recipients
Gene-edited xenograft donor animalsTRL 6
  • United Therapeutics (Revivicor)Company
    Its 10-edit UKidney entered the EXPAND trial at NYU Langone in November 2025; it is building designated-pathogen-free herds, including a $110M facility in Stewartville, Minnesota due to operate in 2027, toward thousands of organs a year
  • eGenesisStartup
    Got FDA IND clearance for the 69-edit EGEN-2784 kidney in September 2025; its expanded-access recipient passed seven months dialysis-free, the longest survival with an engineered porcine organ
  • David AyaresResearcher, Revivicor, United Therapeutics
    Made the original alpha-gal knockout pigs and the multi-edit donor lines used in nearly every US xenotransplant to date
  • Robert MontgomeryResearcher, NYU Langone Transplant Institute
    Performed the first decedent xenokidney transplants (2021) and led the first transplant in the EXPAND clinical trial (November 2025)
Multiplex genome engineeringTRL 6
  • eGenesisStartup
    Its 69-edit Yucatan miniature pigs supply clinical xenotransplants; a kidney from one functioned 271 days in a patient, reported September 2026
  • Colossal BiosciencesStartup
    Made eight simultaneous edits across seven genes in its woolly mouse (March 2025) and 20 edits at 14 loci in a gray wolf cell line
  • George ChurchResearcher, Harvard Medical School and Wyss Institute
    Originated multiplex genome engineering and co-founded both eGenesis and Colossal; the 2025 woolly mouse work used his lab's multiplexing toolset
  • RevivicorCompany
    United Therapeutics subsidiary whose 10-edit pigs produced the first gene-edited pig heart transplants and now supply FDA-cleared xenotransplant trials

Beyond engineering

  • Zoonosis surveillance obligations on recipients for life
  • Animal welfare limits on multi-organ engineered donors
  • Allocation and pricing of a manufactured organ supply